187 related articles for article (PubMed ID: 26884313)
1. Roles of the ER-α36-EGFR/HER2 positive regulatory loops in tamoxifen resistance.
Yin L; Wang ZY
Steroids; 2016 Jul; 111():95-99. PubMed ID: 26884313
[TBL] [Abstract][Full Text] [Related]
2. Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells.
Yin L; Zhang XT; Bian XW; Guo YM; Wang ZY
PLoS One; 2014; 9(9):e107369. PubMed ID: 25203051
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
[TBL] [Abstract][Full Text] [Related]
4. ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway.
Zhu L; Zou J; Zhao Y; Jiang X; Wang Y; Wang X; Chen B
J Exp Clin Cancer Res; 2018 Jun; 37(1):123. PubMed ID: 29940998
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
Zhang X; Wang ZY
Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
[TBL] [Abstract][Full Text] [Related]
8. ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells.
Deng H; Yin L; Zhang XT; Liu LJ; Wang ML; Wang ZY
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():417-26. PubMed ID: 25158023
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway.
Kwon YS; Nam KS; Kim S
Biochem Pharmacol; 2021 Aug; 190():114635. PubMed ID: 34058187
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of ER-α36 expression sensitizes HER2 overexpressing breast cancer cells to tamoxifen.
Yin L; Pan X; Zhang XT; Guo YM; Wang ZY; Gong Y; Wang M
Am J Cancer Res; 2015; 5(2):530-44. PubMed ID: 25973295
[TBL] [Abstract][Full Text] [Related]
11. let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor α signaling in breast cancer.
Zhao Y; Deng C; Lu W; Xiao J; Ma D; Guo M; Recker RR; Gatalica Z; Wang Z; Xiao GG
Mol Med; 2011; 17(11-12):1233-41. PubMed ID: 21826373
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer.
Wang ZY; Yin L
Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():193-206. PubMed ID: 25917453
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor variant ER-α36 promotes tamoxifen agonist activity in glioblastoma cells.
Qu C; Ma J; Zhang Y; Han C; Huang L; Shen L; Li H; Wang X; Liu J; Zou W
Cancer Sci; 2019 Jan; 110(1):221-234. PubMed ID: 30417588
[TBL] [Abstract][Full Text] [Related]
14. Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36.
Shen Y; Zhong J; Liu J; Liu K; Zhao J; Xu T; Zeng T; Li Z; Chen Y; Ding W; Wen G; Zu X; Cao R
Oncol Rep; 2018 Jun; 39(6):2604-2612. PubMed ID: 29620287
[TBL] [Abstract][Full Text] [Related]
15. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.
Zhang X; Deng H; Wang ZY
J Steroid Biochem Mol Biol; 2014 Sep; 143():434-43. PubMed ID: 24973581
[TBL] [Abstract][Full Text] [Related]
16. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.
Shi L; Dong B; Li Z; Lu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Wang Z; Xie Y
J Clin Oncol; 2009 Jul; 27(21):3423-9. PubMed ID: 19487384
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
Gee JM; Robertson JF; Gutteridge E; Ellis IO; Pinder SE; Rubini M; Nicholson RI
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S99-S111. PubMed ID: 16113104
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
Massarweh S; Osborne CK; Creighton CJ; Qin L; Tsimelzon A; Huang S; Weiss H; Rimawi M; Schiff R
Cancer Res; 2008 Feb; 68(3):826-33. PubMed ID: 18245484
[TBL] [Abstract][Full Text] [Related]
19. A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells.
Zhang XT; Kang LG; Ding L; Vranic S; Gatalica Z; Wang ZY
Oncogene; 2011 Feb; 30(7):770-80. PubMed ID: 20935677
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]